Skip to contentL
Lyell Immunopharma, Inc.
L
LYELLyell Immunopharma, Inc. Q1 2024 · 10-Q
Revenue$3.00K$3.00K−95.4% vs Q1 2023 Net Income-$60.67M-$60.67MN/M vs Q1 2023 EPS Diluted-$0.24-$0.24N/M vs Q1 2023 Operating Income-$55,575,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
Free Cash Flowderived-$42,046,000N/M Margins · derivedOperating margin-1852500.0%−1756260.0 pt vs Q1 2023
Net margin-2022233.3%−1919219.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 6, 2024 · 36 d after period end